Telemedicine Adoption Not Linked to Changes in Visits, Spending

Follow Drugslib on

By Elana Gotkine HealthDay Reporter

Medically reviewed by Carmen Pope, Senior Medical Editor, B. Pharm. Last updated on May 12, 2026.

via HealthDay

TUESDAY, May 12, 2026 -- Telemedicine adoption is not associated with changes in visits or spending, according to a study published online May 11 in JAMA Network Open.

John N. Mafi, M.D., M.P.H., from the David Geffen School of Medicine at UCLA in Los Angeles, and colleagues quantified the association between telemedicine adoption and visits and spending for a national sample of adults continuously enrolled in Medicare fee-for-service, Medicare Advantage, dual-eligible, Medicaid, or commercial insurance from Jan. 1, 2019, to Oct. 31, 2023.

The sample included 3.04 million U.S. individuals who had 120 million visits and spending of $178.4 billion during 2019 to 2023. The researchers found that the mean visit rate was 0.66 in 2019, and the mean spending rate was $774.59 per member per month. High-adopting areas had 2.4 percent fewer visits and 0.5 percent lower spending, but the 95 percent confidence intervals crossed the null. There was variation seen in point estimates across subgroups, but none achieved statistical significance: 4.4 percent fewer visits and 2.3 percent lower spending were seen among urban populations; in these populations, 2.5, 5.3, 3.0, and 1.5 percent lower spending was observed for Medicaid-insured individuals, dual-eligible individuals, Medicare Advantage-insured individuals, and the most socially vulnerable populations, respectively. In rural areas, there were 3.4 percent greater visits and 3.8 percent higher spending; 1.1, 1.0, and 4.5 percent higher spending was observed for commercially insured individuals, Medicare fee-for-service-insured individuals, and the least socially vulnerable groups, respectively.

"That is reassuring for anyone worried about ballooning costs, but more sobering for anyone hoping telemedicine would close longstanding gaps in access," Mafi said in a statement.

Several authors disclosed ties to the biopharmaceutical and consulting industries.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2026-05-13 02:44

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords